Amsino International Acquires MedXL Assets to Enhance Manufacturing
Slice of Manufacturing Team
Dec 01, 2024
Key Highlights:
- Amsino acquires MedXL's assets, including IP, facilities, and product registrations in 60+ countries.
- MedXL specializes in prefilled syringes for intravenous drug therapy.
- Acquisition aligns with Amsino's reshoring strategy and supply chain resiliency goals.
- Combined manufacturing capacity to exceed 500 million syringe units annually.
- Innovative MedXL products include Praxiject™, CitraFlow™, and CitraFlow PLUS™ syringes.
Source: PR Newswire
Quotes
“ "The acquisition aligns perfectly with our reshoring strategy to expand our manufacturing footprint to better serve customers in North America." ”
Dr. Richard Lee, Chairman and CEO at Amsino International
Our Take:
This acquisition signifies a pivotal moment in Amsino International’s growth trajectory. By integrating MedXL's state-of-the-art facilities and product portfolio, Amsino reinforces its commitment to supply chain resiliency and innovation in intravenous drug therapy. MedXL’s FDA and globally certified facilities provide Amsino with a competitive edge in North America and beyond, particularly in a healthcare environment increasingly focused on onshore manufacturing and product reliability. This move is likely to solidify Amsino's leadership in the prefilled syringe market while ensuring robust service capabilities across its customer base.
